Support via the Makena Care Connection®—because every woman’s maternity benefits are as unique as she is

A dedicated customer support program that provides individualized prescription support based on the patient’s maternity benefits.

  • To prescribe Makena® (hydroxyprogesterone caproate injection):

Submit the prescription online via eMakena iAssist.com

—or—

Complete the Makena Prescription Form and fax to the Makena Care Connection®

  • Download resources that provide an overview of the Makena Care Connection services and tips to help support you in prescribing Makena
Meet the Makena Care Connection team

Get to know the Makena Care Connection® team

The manager of the Makena Care Connection introduces her team and explains how they can help you navigate the prescription process for patients including prior authorizations and financial assistance when needed.

Learn more about Makena Care Connection services

Monday–Friday, 7 AM – 7 PM (CT)

Committed to helping
ensure cost is not a barrier to
acceptance of therapy

Financial assistance is available with no upper-level income caps for eligible insured and uninsured patients in need. Learn more

Committed to helping patients
adhere to their weekly
injection schedule

The Makena Care Connection offers translation services in approximately 20 different languages

A free nurse-led program designed to provide education, support, and empowerment throughout the patient’s pregnancy journey. Learn more

Committed to helping address
logistical barriers to therapy

Makena @Home provides access to weekly administration of therapy in the home setting via a trusted home healthcare provider when covered by the patient’s insurance. Learn more

Pharmacies

Accredo Health Group, Inc.
1-888-608-9010

BriovaRx of Maine, Inc.
1-855-427-4682

Cigna Tel-Drug Home Delivery Services
1-800-351-3606

CVS Caremark Specialty Pharmacy
1-800-237-2767

Exactus
1-866-458-9246

Exactus
1-866-458-9246

Humana Pharmacy, Inc.
1-855-264-0104

Option Care
1-855-275-9647

Prime Therapeutics Specialty Pharmacy™
1-877-627-6337

Walgreens Specialty Pharmacy
1-888-347-3416

 

Prime Therapeutics Specialty Pharmacy LLC (Prime Specialty Pharmacy) is a wholly owned subsidiary of Prime Therapeutics LLC.

Makena patient and her family
Watch Kate's video about Makena Care Connection

Makena Care Connection® helped Kate through her prescription process

Kate, a busy mother of a toddler, turned to Makena Care Connection when she was pregnant again to help her get started on Makena® (hydroxyprogesterone caproate injection).

3-step prescription process via the Makena Care Connection

Makena Care Connection prescription process

You should receive a confirmation of receipt via fax within a few minutes. If you do not receive this communication, please contact the Makena Care Connection to find out if your patient’s prescription has been received.

1-800-847-3418
—or—
Makena@sonexushealth.com

The results of the investigation will be relayed to both you and your patient over the phone.

  • If the patient cannot afford her out-of-pocket cost, she should ask the Makena Care Coordinator for financial assistance

Once the specialty pharmacy receives approval from the patient’s insurance company, the pharmacy will call the patient to arrange for payment and delivery.

  • If the patient does not respond to this phone call, the pharmacy will not ship the medication
  • If Makena is to be shipped to the healthcare provider’s office, the pharmacy will call the office to confirm the shipping address and ensure that the office will be open on the scheduled delivery date
See how to submit prescriptions

See how the Makena Care Connection® team supports you and your office throughout the prescription submission process

The manager of the Makena Care Connection, introduces you to her team and explains how they are dedicated to helping you submit and process patient prescriptions for Makena® (hydroxyprogesterone caproate injection) to ensure on time initiation of therapy.

Let your patients know that timely communication is important

  • Tell your patients to expect a phone call from the Makena Care Connection and/or the specialty pharmacy
Inform your patients of an upcoming phone call from Makena Care Connection and/or a specialty pharmacy
  • Makena will not be shipped until payment is collected and the shipping address is verified

When in doubt, ask

If you or your patient is ever in doubt regarding the status of the Makena prescription, please contact the Makena Care Connection at 1-800-847-3418 or email Makena@sonexushealth.com.

If you know which pharmacy is dispensing your patient's prescription, you can call it directly.

Makena @Home by Walgreens Infusion Services

If you have questions about your patient's administration of therapy through Makena @Home, please contact the Makena Care Connection at 1-800-847-3418 or email Makena@sonexushealth.com.

Want to purchase Makena for your office? Learn how

Committed to helping ensure cost is not a barrier to acceptance of therapy

Financial assistance for Makena is available with no upper-level income caps for eligible commercially insured and uninsured patients in need

Makena Copay Assistance Makena Copay Assistance
  • Each patient's eligibility is evaluated on an individual basis. Program eligibility criteria are subject to change. Financial assistance programs are administered by the Makena Cares Foundation®, which is managed by Sonexus Health.

Eligibility criteria for the assistance programs include:

  • Patient meets the FDA-approved indication (pregnant with a singleton with a history of singleton spontaneous preterm birth <37 weeks' gestation)1

In compliance with federal regulations, patients insured by a government-funded program (e.g., Medicaid, TRICARE, etc.) are not eligible.

If your patient feels her out-of-pocket cost is too high, she should call the Makena Care Connection to see if she is eligible for financial assistance*

Monday–Friday, 7 AM – 7 PM (CT)

Watch Makena Copay Assistance Program video

Makena Copay Assistance Program for eligible commercially insured patients

Eligible women can reduce their out-of-pocket cost for Makena® (hydroxyprogesterone caproate injection). Learn more about the commitment of AMAG Pharmaceuticals to affordable access to therapy.

Watch Makena Patient Assistance Program video

Makena Patient Assistance Program for eligible uninsured patients

Eligible uninsured women can reduce their out-of-pocket cost for Makena® (hydroxyprogesterone caproate injection). Learn more about the commitment of AMAG Pharmaceuticals to affordable access to therapy.

Forms you may need to complete the Makena prescription process

Makena Prescription Form

Makena Prescription Form

To initiate the Makena prescription process via the Makena Care Connection.

Download
Makena HIPAA form

Makena Authorization for Release of Personal Health Information Form (HIPAA form)

If the patient does not sign Step 2 (Patient Authorization) of the Makena Prescription Form, this form may be completed and faxed to the Makena Care Connection at a later date. The HIPAA release form allows the Makena Care Connection to communicate with the healthcare provider, insurer, and specialty pharmacy on the patient's behalf. Note: this form does not need to be completed if the patient has already signed Step 2 of the Makena Prescription Form.

English Spanish
Indication

Makena (hydroxyprogesterone caproate injection) is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Important safety information for Makena (hydroxyprogesterone caproate injection)
  • Do not use Makena in women with any of the following conditions:
    • Current or history of thrombosis or thromboembolic disorders
    • Known or suspected breast cancer, other hormone-sensitive cancer or history of these conditions
    • Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
    • Cholestatic jaundice of pregnancy
    • Liver tumors, benign or malignant, or active liver disease
    • Uncontrolled hypertension
  • Makena should be discontinued if thrombosis or thromboembolism occurs
  • Allergic reactions, including urticaria, pruritus and angioedema have been reported with use of Makena or with other products containing castor oil
  • Women receiving Makena should be monitored if they:
    • Are prediabetic or diabetic
    • Have conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction
    • Have a history of clinical depression; Makena should be discontinued if depression recurs
    • Develop jaundice; consider whether benefit of use warrants continuation
    • Develop hypertension
  • Certain pregnancy-related fetal and maternal complications or events were numerically increased in Makena-treated subjects as compared to placebo subjects, including miscarriage (2.4% vs. 0%) and stillbirth (2% vs. 1.3%), admission for preterm labor (16% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%), and oligohydramnios (3.6% vs. 1.3%)
  • The most common adverse reactions reported in ≥2% of subjects and at a higher rate in the Makena group than in the control group were injection site reactions (pain [35% vs. 33%], swelling [17% vs. 8%], pruritus [6% vs. 3%], and nodule [5% vs. 2%]), urticaria (12% vs. 11%), pruritus (8% vs. 6%), nausea (6% vs. 5%), and diarrhea (2% vs. 1%)

Please see full prescribing information for Makena.

Reference: 1. Makena® (hydroxyprogesterone caproate injection) prescribing information, AMAG Pharmaceuticals, 2016.

Important safety information and Indication
INDICATION
IMPORTANT SAFETY INFORMATION
Top